Human cytokines suppress apoptosis of leukaemic CD5+ B cells and preserve expression of bcl-2
- PMID: 9107564
- DOI: 10.1038/icb.1997.17
Human cytokines suppress apoptosis of leukaemic CD5+ B cells and preserve expression of bcl-2
Abstract
Leukaemic CD5+ B cells obtained from B cell chronic lymphocytic leukaemia (B-CLL) patients rapidly undergo apoptosis during in vitro culture. This is associated with down-regulation in expression of bcl-2. Spontaneous apoptosis of these cells contrasts their enhanced longevity in vivo and suggests that apoptosis-inhibitory factors may be responsible for the accumulation of leukaemic cells in B-CLL. The effect of different cytokines on apoptosis and bcl-2 expression was examined in six populations of leukaemic CD5+ B cells. Consistent with previous data, IL-4 and IFN-gamma suppressed apoptosis in 6/6 and 5/6 cell populations, respectively. Interestingly, the ability to suppress apoptosis in leukaemic CD5+ B cells was also found to be a property of IL-2, IL-6, IL-13 and TNF-alpha. In the presence of these cytokines, 10-40% more viable cells were detected, compared with unstimulated cultures. Enhancement of cell viability and suppression of apoptosis were associated with a delay in down-regulation of bcl-2. These results suggest a role for autocrine and paracrine growth factors in the pathogenesis of B-CLL, and indicate that cytokines which prevent apoptosis in vitro may be targets for treating this malignancy.
Similar articles
-
Modulation of apoptosis with cytokines in B-cell chronic lymphocytic leukaemia.Leuk Lymphoma. 1996 May;21(5-6):369-77. doi: 10.3109/10428199609093434. Leuk Lymphoma. 1996. PMID: 9172801 Review.
-
Interleukin-10 inhibits the in vitro proliferation of human activated leukemic CD5+ B-cells.Leuk Lymphoma. 1998 Sep;31(1-2):121-30. doi: 10.3109/10428199809057592. Leuk Lymphoma. 1998. PMID: 9720722
-
Cytokines and cross-linking of sIgM augment PMA-induced activation of human leukaemic CD5+ B cells.Immunol Cell Biol. 1997 Dec;75(6):561-7. doi: 10.1038/icb.1997.87. Immunol Cell Biol. 1997. PMID: 9492192
-
In leukaemic CD5+ B cells the expression of BCL-2 gene family is shifted toward protection from apoptosis.Br J Haematol. 1996 Sep;94(4):612-8. doi: 10.1046/j.1365-2141.1996.d01-1856.x. Br J Haematol. 1996. PMID: 8826882
-
Interferon-alpha, Bcl-2 expression and apoptosis in B-cell chronic lymphocytic leukemia.Leuk Lymphoma. 1996 Mar;21(1-2):43-7. doi: 10.3109/10428199609067578. Leuk Lymphoma. 1996. PMID: 8907268 Review.
Cited by
-
Rituximab for the treatment of patients with chronic lymphocytic leukemia.Cancer Manag Res. 2010 Mar 11;2:71-81. doi: 10.2147/cmar.s5621. Cancer Manag Res. 2010. PMID: 21188098 Free PMC article.
-
Tumor Cell Survival Factors and Angiogenesis in Chronic Lymphocytic Leukemia: How Hot Is the Link?Cancers (Basel). 2024 Dec 29;17(1):72. doi: 10.3390/cancers17010072. Cancers (Basel). 2024. PMID: 39796700 Free PMC article. Review.
-
Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers.Leuk Res. 2011 Mar;35(3):394-404. doi: 10.1016/j.leukres.2010.08.001. Epub 2010 Sep 22. Leuk Res. 2011. PMID: 20863567 Free PMC article.
-
Expression of multidrug resistance-associated ABC transporters in B-CLL is independent of ZAP70 status.J Cancer Res Clin Oncol. 2010 Mar;136(3):403-10. doi: 10.1007/s00432-009-0670-9. Epub 2009 Sep 1. J Cancer Res Clin Oncol. 2010. PMID: 19727816 Free PMC article.
-
Apoptosis in B-chronic lymphocytic leukaemia.Med Oncol. 1998 Dec;15(4):234-40. doi: 10.1007/BF02787206. Med Oncol. 1998. PMID: 9951686 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources